David F. Jarrard, MD Print Friendly Page
Faculty, University of Wisconsin School of Medicine and Public HealthDr. Jarrard is board certified by the American Board of Urology and has completed a fellowship in Urologic Oncology. He specializes in all aspects of urologic oncology with an emphasis on prostate cancer diagnosis and treatment. Dr. Jarrard is also involved with surgical treatments for prostate cancer, such as the robotic prostatectomy.
Specialties
Clinics
UW School of Medicine and Public Health
| Department of Urology |
Professional Certifications and Education
| Board Certification |
Urology
|
| Fellowship |
Urologic Oncology, The Johns Hopkins Hospital, Baltimore, MD
|
| Residency |
University of Chicago Medical Center, Chicago, IL
|
| Internship |
University of Chicago Medical Center, Chicago, IL
|
| Medical School |
University of Virginia School of Medicine, Charlottesville, VA
|
| Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000. |
| Research |
Dr. Jarrard has a joint appointment with the University of Wisconsin Carbone Cancer Center, and his clinical research emphasizes developing new therapies for genitourinary cancers. He has an active basic science laboratory and is funded through the National Institutes of Health to examine genetic and epigenetic alterations in prostate cancer. |
PubMed Articles
-
Etheridge T Liou JI Downs TM Abel EJ Jarrard DF Richards KA
The Impact of Agent Orange Exposure on Prostate Cancer Outcomes. J Urol . 2019 Apr;201(4):742-750
[PubMed ID: 30321553]
-
Damodaran S Lang JM Jarrard DF
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches. J Urol . 2019 Feb 7;:101097JU0000000000000117
[PubMed ID: 30747897]
-
Anderson-Carter I Posielski N Liou JI Khemees TA Downs TM Abel EJ Jarrard DF Richards KA
The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study. Urol Oncol . 2019 Feb;37(2):130-137
[PubMed ID: 30528885]
-
Etheridge T Damodaran S Schultz A Richards KA Gawdzik J Yang B Cryns V Jarrard DF
Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier. Asian J Urol . 2019 Jan;6(1):57-64
[PubMed ID: 30775249]
-
Richards KA Liou JI Cryns VL Downs TM Abel EJ Jarrard DF
Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. J Urol . 2018 Dec;200(6):1256-1263
[PubMed ID: 29940252]
-
Etheridge T Straus J Ritter MA Jarrard DF Huang W
Semen AMACR protein as a novel method for detecting prostate cancer. Urol Oncol . 2018 Dec;36(12):532.e1-532.e7
[PubMed ID: 30337219]
-
Spiniello M Knoener RA Steinbrink MI Yang B Cesnik AJ Buxton KE Scalf M Jarrard DF Smith LM
HyPR-MS for Multiplexed Discovery of MALAT1, NEAT1, and NORAD lncRNA Protein Interactomes. J Proteome Res . 2018 Sep 7;17(9):3022-3038
[PubMed ID: 29972301]
-
Maciolek KA Best SL Lopez V Posielski N Knoedler M Bushman WA Jarrard DF Downs TM Abel EJ Richards KA
Effectiveness of a transrectal prostate needle biopsy protocol with risk-tailored antimicrobials in a veterans cohort. Urol Oncol . 2018 Aug;36(8):363.e13-363.e20
[PubMed ID: 29887242]
-
Etheridge T Liou J Downs TM Abel EJ Richards KA Jarrard DF
The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy. Am J Clin Exp Urol . 2018;6(3):123-132
[PubMed ID: 30038944]
-
Gravis G Boher JM Chen YH Liu G Fizazi K Carducci MA Oudard S Joly F Jarrard DM Soulie M Eisenberger MJ Habibian M Dreicer R Garcia JA Hussain MHM Kohli M Vogelzang NJ Picus J DiPaola R Sweeney C
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol . 2018 Jun;73(6):847-855
[PubMed ID: 29475737]
-
Cesnik AJ Yang B Truong A Etheridge T Spiniello M Steinbrink MI Shortreed MR Frey BL Jarrard DF Smith LM
Long Noncoding RNAs AC009014.3 and Newly Discovered XPLAID Differentiate Aggressive and Indolent Prostate Cancers. Transl Oncol . 2018 Jun;11(3):808-814
[PubMed ID: 29723810]
-
Morgans AK Chen YH Sweeney CJ Jarrard DF Plimack ER Gartrell BA Carducci MA Hussain M Garcia JA Cella D DiPaola RS Patrick-Miller LJ
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol . 2018 Apr 10;36(11):1088-1095
[PubMed ID: 29522362]
-
Kyriakopoulos CE Chen YH Carducci MA Liu G Jarrard DF Hahn NM Shevrin DH Dreicer R Hussain M Eisenberger M Kohli M Plimack ER Vogelzang NJ Picus J Cooney MM Garcia JA DiPaola RS Sweeney CJ
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol . 2018 Apr 10;36(11):1080-1087
[PubMed ID: 29384722]
-
Sierra PS Damodaran S Jarrard D
Clinical and pathologic factors predicting reclassification in active surveillance cohorts. Int Braz J Urol . 2018 Mar-Apr;44(3):440-451
[PubMed ID: 29368876]
-
Richards KA Ruiz VL Murphy DR Downs TM Abel EJ Jarrard DF Singh H
Diagnostic evaluation of patients presenting with hematuria: An electronic health record-based study. Urol Oncol . 2018 Mar;36(3):88.e19-88.e25
[PubMed ID: 29169843]
-
Harshman LC Chen YH Liu G Carducci MA Jarrard D Dreicer R Hahn N Garcia JA Hussain M Shevrin D Eisenberger M Kohli M Plimack ER Cooney M Vogelzang NJ Picus J Dipaola R Sweeney CJ ECOG-ACRIN 3805 Investigators.
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol . 2018 Feb 1;36(4):376-382
[PubMed ID: 29261442]
-
Johnson BP Vitek RA Geiger PG Huang W Jarrard DF Lang JM Beebe DJ
Vital ex vivo tissue labeling and pathology-guided micropunching to characterize cellular heterogeneity in the tissue microenvironment. Biotechniques . 2018 Jan 1;64(1):13-19
[PubMed ID: 29384072]
-
Damodaran S Damaschke N Gawdzik J Yang B Shi C Allen GO Huang W Denu J Jarrard D
Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes. BMC Cancer . 2017 Dec 20;17(1):874
[PubMed ID: 29262808]
-
Lee JH Yang B Lindahl AJ Damaschke N Boersma MD Huang W Corey E Jarrard DF Denu JM
Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development. ACS Chem Biol . 2017 Nov 17;12(11):2804-2814
[PubMed ID: 28949514]
-
Damodaran S Kyriakopoulos CE Jarrard DF
Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed? Urol Clin North Am . 2017 Nov;44(4):611-621
[PubMed ID: 29107277]